新京报讯（记者张兆慧）6月6日，由北京医师协会减重与代谢专科医师分会、首都医科大学附属北京友 谊医院主办，望京SOHO联合主办，中国肥胖联盟学术支持、首都14家大型医院参与的"科学减重蓝蜻 蜓行动"之"首都减重名医面对面咨询公益行"活动在望京SOHO中央广场举办。本次活动旨在推进落 实"体重管理年"行动，普及健康生活方式，提升群众体重健康意识，推动肥胖症的科学防治。 "情绪型肥胖、外卖、久坐等都是导致职场人士肥胖的常见原因，而肥胖可能导致人们出现血脂异常、 脂肪肝、高尿酸、高血压等慢性疾病。"张鹏建议，职场人士应把运动融入工作中，每工作半个小时就 离开座位站一站、蹲一蹲、跳一跳；上下班不要长时间开车，可以选择公交、自行车等方式，或者将车 停远一点，给自己留一段走路的距离；注意调节情绪，尽量避免在过度高兴或过度伤心时报复性饮食。 肥胖防控是一场持久战，需要全社会共同努力。张鹏表示，本次"首都减重名医面对面"活动有效科普了 体重管理理念，可以提高人们对体重管理的重视度，并为有减重需求的人士提供科学指导。未来，中国 肥胖联盟还将持续推动"科学减重蓝蜻蜓行动"，开展更多线上线下健康科普、社区健康咨询等公益活 动，推动 ...

Group 1 - Guangzhou launched the 2025 National Health Literacy Promotion Month and Weight Management Year with the theme "Control Weight, Improve Literacy, Enjoy Health" [1] - The overweight rate among the population aged 20-79 in Guangzhou is 33.9%, and the obesity rate is 11.9%, which, although lower than the national average, remains a concern [1] - The focus of weight management is on reducing body fat rather than just weight, emphasizing the importance of controlling excess visceral fat [1] Group 2 - Guangzhou has established a health literacy framework through legislation, including the first local law on health promotion and education, providing legal support for improving residents' health literacy [2] - A health science popularization expert database has been created, gathering 886 experts and over 8,800 medical volunteers to conduct health education activities in communities [2] - The Guangzhou Health Commission, in collaboration with 12 departments, has issued a work plan for the "Weight Management Year" initiative, designating 63 hospitals to set up weight management clinics and creating a map for easy access [2]

Core Viewpoint - The article emphasizes the need for a systemic approach to obesity management, recognizing it as a medical condition rather than a personal failure, and highlights the importance of integrating medical intervention, public policy, and societal support in addressing obesity [5][10][22]. Summary by Sections Current State of Obesity in China - As of 2018, the overweight rate among Chinese residents aged 18 and above was 34.3%, with an obesity rate of 16.4%, translating to over 182 million adults suffering from obesity [5]. - The perception of obesity as merely a lifestyle choice has led to delayed treatment for many patients [5][10]. Medical Recognition and Policy Response - Obesity is classified as a disease by the World Health Organization since 1997, and recent guidelines emphasize its multifactorial causes, including genetics and environment [10][11]. - The Chinese government is actively promoting obesity management through initiatives like the "Health China 2030" strategy and the "Weight Management Year" campaign, aiming for comprehensive coverage of weight management clinics by June 2025 [5][8][12]. Societal and Medical Shifts - There is a growing recognition that obesity requires medical intervention, with new weight-loss medications like GLP-1 receptor agonists gaining attention [6][16]. - Public awareness is shifting, with over 70% of respondents supporting the inclusion of obesity prevention in national health strategies [19][23]. Treatment Approaches and Innovations - A multi-disciplinary approach is being adopted in obesity treatment, integrating lifestyle changes, medication, and potentially surgery for severe cases [18]. - The establishment of specialized weight management clinics is on the rise, with innovative service models being developed to provide comprehensive care [13][20]. Community and Public Health Initiatives - Local health authorities are creating supportive environments for weight management, including health parks and community fitness facilities [14][22]. - Collaborative efforts among government, medical institutions, and private sectors are essential for effective obesity management and chronic disease prevention [22][23].

Core Viewpoint - The article emphasizes the urgent need for weight management in China, highlighting the significant health risks associated with overweight and obesity, and outlines a comprehensive action plan to improve public awareness and management of body weight by 2030 [5][7]. Action Goals - By 2030, a supportive environment for weight management will be widely established, enhancing public awareness and capabilities regarding healthy lifestyles, and curbing the growth of overweight and obesity populations [7]. Individual and Family - Individuals and families should recognize the importance of weight management, understand the health risks of being overweight or obese, and learn about the impact of diet, exercise, sleep, and mental health on body weight [8]. - Families are encouraged to actively participate in weight management by adopting healthy lifestyles, promoting balanced diets, and encouraging regular physical activity among all members [9]. - It is recommended that families equip themselves with tools for weight management, such as scales and measuring tapes, and focus on the weight management of children and adolescents [10]. Society and Government - There is a need to strengthen scientific education and public awareness regarding weight management, utilizing media and community resources to promote balanced diets and physical activity [11]. - Professional healthcare providers should be trained to offer guidance on weight management, integrating it into disease prevention and clinical care [11]. - Creating a supportive social environment is essential, including the development of health-themed parks and facilities, and promoting healthy eating in schools [12]. - Advocating for healthy consumption practices and the development of new weight management technologies and products is crucial [12]. - Continuous monitoring of weight levels and influencing factors is necessary to guide weight management efforts effectively [13].

Core Viewpoint - Veru Inc. is advancing its late-stage clinical development of enobosarm, showing promising safety and efficacy data in combination with semaglutide for weight management in elderly patients [1][2][8]. Group 1: Safety and Efficacy of Enobosarm - The combination of enobosarm with semaglutide demonstrated good safety, with no increase in gastrointestinal adverse events or signs of drug-induced liver injury [2][3]. - No serious adverse events related to treatment were reported, with only four non-treatment-related serious adverse events observed [2][3]. - Enobosarm 3mg combined with semaglutide resulted in fewer gastrointestinal discomfort reports compared to the placebo plus semaglutide group [2][3]. Group 2: Primary and Secondary Endpoints - The study achieved its primary endpoint, showing that enobosarm combined with semaglutide significantly reduced lean body mass loss, with the 3mg group showing a 99.1% relative reduction in lean mass loss compared to placebo (p<0.001) [4][6]. - Enobosarm promoted fat loss in a dose-dependent manner, with the 6mg group showing a 46% reduction in fat compared to placebo at 16 weeks (p=0.014) [5][6]. Group 3: Functional Improvement - The stair climbing test indicated that only 16% of participants in the enobosarm 3mg group experienced a decline of 10% or more, representing a 62.4% reduction in decline risk compared to the placebo group (p=0.0066) [7]. - In contrast, 42.6% of the placebo plus semaglutide group showed a decline of 10% or more in the stair climbing test [7]. Group 4: Future Outlook - The QUALITY study is the first to validate the risk of accelerated lean mass loss and functional decline in elderly patients using GLP-1 receptor agonists for weight management [8]. - Veru plans to further develop enobosarm as a combination treatment with GLP-1 agonists to protect muscle mass and prevent functional decline during weight loss [8].

Core Viewpoint - Maintaining stable body weight is associated with increased longevity, particularly among older women, as evidenced by a study published in the "Journal of Gerontology" which indicates that those who keep their weight stable have a higher likelihood of living to 90 years or older [7]. Group 1: Importance of Weight Stability - A study involving 54,437 women aged 61 to 81 found that 56% lived to at least 90 years old, with those maintaining stable weight having a 1.2 to 2 times higher chance of longevity compared to those who lost 5% or more of their body weight [7]. - Weight gain of 5% or more showed no significant correlation with longevity [7]. Group 2: Understanding Obesity - Obesity is influenced by various factors including genetics, diet, physical activity, lifestyle, and social environment [9]. - Body Mass Index (BMI) is a common tool for assessing weight status, with healthy adults having a BMI between 18.5 and 24, overweight classified as 24 to 28, and obesity at 28 or above [9]. Group 3: Weight Management Strategies - Effective weight loss strategies should focus on dietary control and increased physical activity, with a recommended gradual weight loss of 5% to 10% over six months [11]. - The National Health Commission has released guidelines for healthy eating to support weight management, emphasizing the importance of balanced nutrition [11][12]. Group 4: Dietary Recommendations - Suggested dietary practices include prioritizing whole grains, lean proteins, low-fat dairy, and a variety of fresh fruits and vegetables while controlling sugar and starch intake [14]. - Daily caloric intake should be adjusted based on individual needs, with recommendations for men to consume 1,200 to 1,500 kcal and women 1,000 to 1,200 kcal [15].

以下文章来源于体重管理三年行动 ，作者体重管理三年行动 体重管理三年行动 . 响应国家"健康中国2030"战略，落实"体重管理年"三年行动，本账号发布权威资讯 近日，"国家喊你减肥"这一话题持续升温，"体重管理"理念正悄然走入高校，并迅速引发热潮。各大高校也在推动"体重管理"方面下足了功 夫，从饮食管控到锻炼指导，纷纷推出多项举措，助力大学生健康减重，积极培养良好的生活习惯。 在北京大学，《体能提升：运动与膳食》成为最受欢迎的体育课程之一。为何体育课要花心思教大家如何饮食？主讲老师张晓圆是运动营养学 专家，她认为，减重不仅要多运动，还要注重饮食控制，做到摄入的热量少于消耗的热量。张老师会为每位同学量身定制膳食计划，并带学生 走进食堂，手把手教大家如何科学搭配，既能控制热量，又能吃得饱、有营养。 ▍北科大推出复刻版卫健委食谱"减脂套餐" 每到用餐时间，北京科技大学食堂的这个小窗口前总是排满了等待的学生，大家都在抢购新推出的减脂餐。紫米饭、带鱼、绿豆芽，再加上一 碗酸奶，搭配虽简单，却备受欢迎。这款减脂套餐正是学校食堂根据国家卫健委2024年新版《成人肥胖食养指南》专门研发推出的健康选择。 北京科技大学后勤管理处 ...

在肥胖治疗领域，GLP-1（胰高血糖素样肽-1）靶点的价值已被广泛认可。作为重要的肠促胰素，GLP- 1通过激活GLP-1受体，既能调节血糖，又能作用于中枢抑制食欲、延缓胃排空以减少能量摄入。而 GCG（胰高血糖素）靶点的研究则为肥胖治疗打开了新视野。GCG由胰岛α细胞分泌，其受体 （GCGR）的激活可增强脂肪氧化、促进能量消耗，尤其在改善肝脏脂肪代谢方面具有独特潜力。GCG 与GLP-1靶点联用，可以通过"抑制食欲+加速代谢"的双重机制，更全面地解决肥胖患者内脏脂肪堆 积、胰岛素抵抗等复杂代谢问题，突破单一靶点的治疗局限。 "玛仕度肽（1BI362）是一种每周一次给药的GCG/GLP-1双受体激动剂。"纪立农介绍，在Ⅱ期临床试验 中，玛仕度肽6mg在中国超重或肥胖受试者和2型糖尿病受试者中均显示出显著的体重减轻效果，且其 耐受性和安全性与GLP-1受体激动剂及其联合激动剂相似。纪立农表示，此次入选《新英格兰医学杂 志》的研究，是首个在中国超重或肥胖受试者中评估玛仕度肽疗效和安全性的Ⅲ期临床试验（GLORY- 1）。该研究共入组610名受试者，结果显示各剂量玛仕度肽相较安慰剂均可显著降低体重。同时，患者 在血 ...

瞄准全球化的健康需求，国内外多家药企纷纷投入力量研制新药，在探索肥胖治疗的道路上迈出关键一 步。 玛仕度肽研发企业信达生物的有关负责人表示，将继续瞄准前沿，跑出国产新药创制"加速度"。同时， 药物疗法只是肥胖防控的一环，应对超重和肥胖，重点是构建公共卫生综合防治体系。 北京医院·国家老年医学中心内分泌科首席专家郭立新介绍，当前，肥胖症治疗还存在认知不足、治疗 选择有限、复发率高、多学科协作不够紧密等挑战，需要从单一减重向代谢管理逐步转型，构建以患者 为中心的预防、治疗、随访全程管理。 随着我国医药行业创新能力提升，"十四五"以来，国产创新药"量""质"齐升，多款原创药物取得突破性 进展，并陆续在海外获批上市。国家药监局数据显示，2024年我国批准上市创新药48个，在研新药数量 跃居全球第二位。 国际顶级医学期刊《新英格兰医学杂志》日前在线发表了由我国科研团队主导的肥胖治疗新药——玛仕 度肽Ⅲ期临床研究成果。这意味着，中国在内分泌代谢领域的这一创新成果得到国际认可。 研究牵头人、北京大学人民医院内分泌科主任纪立农5月27日介绍，研究显示，玛仕度肽4毫克和6毫克 治疗32周和48周均展现出较好的减重疗效，同时可降 ...

Core Viewpoint - The article highlights the successful Phase III clinical trial results of the obesity treatment drug Masitide (GCG/GLP-1 dual receptor agonist), which has been published in the prestigious New England Journal of Medicine (NEJM), marking a significant milestone for China's innovation in the field of endocrine metabolism and potentially transforming obesity treatment globally [1][5][10]. Group 1: Clinical Research and Results - The GLORY-1 study, which included 610 participants, demonstrated that Masitide significantly reduced body weight compared to placebo, with 73.9% and 82.0% of participants in the 4 mg and 6 mg groups, respectively, achieving a weight loss of ≥5% by week 32 [9]. - By week 48, 35.7% and 49.5% of participants in the 4 mg and 6 mg groups, respectively, achieved a weight loss of ≥15%, while only 2.0% in the placebo group did [9]. - The drug also showed significant improvements in various metabolic indicators, including blood lipids, blood pressure, and liver fat content [9]. Group 2: Significance and Implications - The publication of the study in NEJM signifies international recognition of China's innovative drug development in the field of obesity treatment, providing a new direction for global obesity management [3][6]. - The research results are expected to influence clinical guidelines and practices, contributing to the "Healthy China 2030" initiative by addressing the rising obesity rates in the country [6][10]. - The dual-target mechanism of Masitide, which combines appetite suppression and enhanced fat metabolism, represents a breakthrough in obesity treatment strategies [8][10]. Group 3: Broader Context and Public Health - The increasing prevalence of overweight and obesity in China poses significant public health challenges, with obesity-related deaths accounting for 11.1% of chronic non-communicable disease deaths in 2019 [4]. - The Chinese government has initiated a "Weight Management Year" campaign to address these issues, emphasizing the importance of weight management in improving national health [4][6]. - Experts suggest that obesity treatment should consider local population characteristics and implement differentiated strategies, particularly focusing on liver health and lipid management [6][10].